Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

• Hoofdauteurs: Diansong Zhou (Auteur), Terry Podoll (Auteur), Yan Xu (Auteur), Ganesh Moorthy (Auteur), Karthick Vishwanathan (Auteur), Joseph Ware (Auteur), J. Greg Slatter (Auteur), Nidal Al‐Huniti (Auteur)
• Formaat: Boek
• Gepubliceerd in: Wiley, 2019-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug-drug interactions (DDIs). The...